SAB Biotherapeutics, Inc.

SABS Financials — Income Statement, Margins & Balance Sheet

Revenue, net income, margins, cash and debt for SABS, built from reported filings and live market data.

$2.95-1.67% todayUSD · live quote
★ ZCoreAI PREMIUM7 days free

Unlock Full SABS Analysis

Explore Z-Score, Smart Money signals, all timeframes and Premium indicators for SABS.

✓Z-Score signals
✓Smart Money flow
✓All timeframes
✓Premium indicators
Start 7-Day Free Trial →

7-day free trial. No commitment during the trial.

SABS Income Statement (TTM)

—
Trailing twelve-month revenue reported by SABS.
Net income (TTM)
-$71.53M
EPS (TTM)
$-2.71
Gross margin
—
Operating margin
-2388.9%
Net margin
-1795.8%
Revenue growth
-64.7%

SABS Revenue vs Net Income by Fiscal Year

Light bars are revenue, solid bars are net income. The gap between them is the cost of running the business — when it narrows, margins are expanding.

FY 2021 revenue $60.88MFY 2022 revenue $11.80MFY 2022 revenue $6.35MFY 2022 revenue $3.59MFY 2022 revenue $2.16MFY 2023 revenue $1.27MFY 2024 revenue $0FY 2025 revenue -$1.27M

SABS Financial Results by Period

The last 12 reported periods for SABS, most recent first.

PeriodRevenueNet incomeNet marginEPS
Q3 2026—-$22.30M—$-0.29
Q2 2026—-$22.49M—$-0.27
Q1 2026—-$18.87M—$-0.35
FY 2025-$1.27M———
FY 2024$0———
FY 2023$1.27M———
FY 2022$2.16M———
Q4 2022—-$7.87M—$-1.80
FY 2022$3.59M———
Q3 2022—-$7.08M—$-1.60
FY 2022$6.35M———
Q2 2022—-$4.78M—$-1.10

SABS Balance Sheet & Cash Generation

Cash, debt, share count and free cash flow — the inputs that decide whether SABS can fund growth without diluting shareholders.

Cash
$110.88M
Total debt
$0
Net cash / (debt)
$110.88M
Shares outstanding
0.09B
Free cash flow
-$58.57M
FCF yield
-21.8%
Market cap
$268.42M
Price / sales
—

Financials vs Valuation & Market Positioning

The statements tell you what the business earns; the multiples and Z-Score tell you what the market is currently charging for it.

Trailing P/E
—
Forward P/E
—
EPS growth
—
Revenue growth
-64.7%

Z-Score readings for SABS are not available right now.

How This SABS Financial Data Is Built

Revenue, net income and EPS come from SABS's reported filings through live ZCoreAI market endpoints. Trailing twelve-month figures sum the last four reported quarters, and net margin per period is net income divided by revenue for that same period. Gross and operating margins are taken from the reported profitability block.

Cash, debt and share count come from the latest published balance sheet; where a figure is absent, free cash flow is approximated from reported net income and shares are derived from market cap divided by price. Price to sales, FCF yield and the multiples use the live quote, so they update on every page load. Nothing here is investment advice.

SABS Financials FAQ

How much revenue does SABS generate?

Trailing revenue for SABS is not available from reported filings right now.

Is SABS profitable?

SABS runs a -1795.8% net margin, equal to -$71.53M of trailing net income.

Does SABS have too much debt?

SABS carries $0 of total debt against $110.88M of cash, a net cash position of $110.88M. Compare that against free cash flow of -$58.57M to judge how quickly it could be repaid.

What is SABS's free cash flow?

SABS generated negative free cash flow of -$58.57M, a -21.8% yield on the current market cap. Free cash flow is what funds buybacks, dividends and debt repayment.

Where does ZCoreAI get SABS financial data?

Revenue, net income, EPS, margins and balance sheet items come from live ZCoreAI market endpoints sourced from company filings, refreshed on every page load.

SABS earnings

Quarterly EPS history, revenue trend and growth for SABS.

SABS P/E ratio

Trailing and forward multiples, PEG and earnings yield for SABS.

SABS forecast

DCF fair value, price prediction and signal targets for SABS.

SABS overview

Live chart, fundamentals and valuation context for SABS.

Research tools we use

  • Koyfin

    Financial data, screening and market research dashboards.

  • Stock Rover

    Stock screening and fundamental research for dividend and value investors.

Data refreshed from live ZCoreAI market endpoints. Informational only — not investment advice.